ReviewViruses2011
Antiviral inhibition of enveloped virus release by tetherin/BST-2: action and counteraction.
Review in Viruses, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 101 citations in OpenAlex.
- Preservation of tetherin and CD4 counter-activities in circulating Vpu alleles despite extensive sequence variation within HIV-1 infected individuals.PLoS pathogens · 2014Trial
- Dynamics of antiretroviral restriction factor expression in sheep naturally infected with Small ruminant lentivirus (SRLV).Archives of virology · 2026Article
- Systemic removal of host restriction factors enables rapid, scalable virus production for cell culture-based vaccine development.Frontiers in bioengineering and biotechnology · 2026Article
- Single-cell RNA-seq provides insight into the underdeveloped immune system of germ-free mice.Zoological research · 2025Article
- Antagonism of BST2/Tetherin, a new restriction factor of respiratory syncytial virus, requires the viral NS1 protein.PLoS pathogens · 2024Article
- Involvement of Human Cellular Proteins and Structures in Realization of the HIV Life Cycle: A Comprehensive Review, 2024.Viruses · 2024Review
- HIV vaccination: Navigating the path to a transformative breakthrough-A review of current evidence.Health science reports · 2024Article
- TLR-mediated aggresome-like induced structures comprise antimicrobial peptides and attenuate intracellular bacterial survival.Molecular biology of the cell · 2024Article
- Article
- Rapid activation of hematopoietic stem cells.Stem cell research & therapy · 2023Article
- ATG5 selectively engages virus-tethered BST2/tetherin in an LC3C-associated pathway.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- HIV-Host Cell Interactions.Cells · 2023Review
- Editorial: Advances in host-pathogen interactions for diseases in animals and birds.Frontiers in veterinary science · 2023Article
- Cell-targeted vaccines: implications for adaptive immunity.Frontiers in immunology · 2023Review
- Interferon Control of Human Coronavirus Infection and Viral Evasion: Mechanistic Insights and Implications for Antiviral Drug and Vaccine Development.Journal of molecular biology · 2022Review
- Catch Me if You Can: the Crosstalk of Zika Virus and the Restriction Factor Tetherin.Journal of virology · 2022Article
- Screening of Gene Expression Markers for Corona Virus Disease 2019 Through Boruta_MCFS Feature Selection.Frontiers in public health · 2022Article
- Human Immunodeficiency Virus Type 1 Vif Up-Regulates the Expression of TatFrontiers in microbiology · 2022Article
- Zn-Induced Interactions Between SARS-CoV-2 orf7a and BST2/Tetherin.ChemistryOpen · 2021Article
- Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Tetherin (BST2/CD317) has been recently recognized as a potent interferon-induced antiviral molecule that inhibits the release of diverse mammalian enveloped virus particles from infected cells. By targeting an immutable structure common to all these viruses, the virion membrane, evasion of this antiviral mechanism has necessitated the development of specific countermeasures that directly inhibit tetherin activity. Here we review our current understanding of the molecular basis of tetherin's mode of action, the viral countermeasures that antagonize it, and how virus/tetherin interactions may affect viral transmission and pathogenicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.